Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Juliana S. Nakamuta, Ana Lia Pradella Puglia, Paula Meireles, Daniela Cavalet Blanco, Marina Andrade Lima, Marina Gabriela Birck, Marion Coting Braga, Renato Watanabe de Oliveira, Guilherme Silva Julian & Francisco Jose Forestiero. (2023) Asthma control in Brazil: a systematic review. Journal of Asthma 60:5, pages 868-880.
Read now
Read now
Joseph W Lanario & Lorna Burns. (2021) Use of Health Related Quality of Life in Clinical Trials for Severe Asthma: A Systematic Review. Journal of Asthma and Allergy 14, pages 999-1010.
Read now
Read now
Kenneth M. Faulkner, Karen MacDonald, Ivo Abraham, Abdulaziz Alhossan & Christopher S. Lee. (2021) ‘Real-world’ effectiveness of omalizumab in adults with severe allergic asthma: a meta-analysis. Expert Review of Clinical Immunology 17:1, pages 73-83.
Read now
Read now
Federica Porcaro, Renato Cutrera & Giovanni Battista Pajno. (2019) Options of immunotherapeutic treatments for children with asthma. Expert Review of Respiratory Medicine 13:10, pages 937-949.
Read now
Read now
Karen M. MacDonald, Abhishek Kavati, Benjamin Ortiz, Abdulaziz Alhossan, Christopher S. Lee & Ivo Abraham. (2019) Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018. Expert Review of Clinical Immunology 15:5, pages 553-569.
Read now
Read now
Stephanie Chen, Sarowar Golam, Julie Myers, Chris Bly, Harry Smolen & Xiao Xu. (2018) Systematic literature review of the clinical, humanistic, and economic burden associated with asthma uncontrolled by GINA Steps 4 or 5 treatment. Current Medical Research and Opinion 34:12, pages 2075-2088.
Read now
Read now
Jonathan Corren, Abhishek Kavati, Benjamin Ortiz, Ashok Vegesna, Jennifer A. Colby, Kimberly Ruiz & Reynold A. Panettieri$suffix/text()$suffix/text(). (2018) Patient-reported outcomes in moderate-to-severe allergic asthmatics treated with omalizumab: a systematic literature review of randomized controlled trials. Current Medical Research and Opinion 34:1, pages 65-80.
Read now
Read now
Zahi Nachef, Amita Krishnan, Terry Mashtare, Tingting Zhuang & M. Jeffery Mador. (2018) Omalizumab versus Mepolizumab as add-on therapy in asthma patients not well controlled on at least an inhaled corticosteroid: A network meta-analysis. Journal of Asthma 55:1, pages 89-100.
Read now
Read now
J. Mark FitzGerald, Catherine Lemiere, M. Diane Lougheed, Francine M. Ducharme, Sharon D. Dell, Clare Ramsey, M. Connie L. Yang, Andréanne Côté, Wade Watson, Ron Olivenstein, Anne Van Dam, Cristina Villa-Roel & Roland Grad. (2017) Recognition and management of severe asthma: A Canadian Thoracic Society position statement. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine 1:4, pages 199-221.
Read now
Read now
Cibele Suzuki, Nilceia Lopes da Silva, Praveen Kumar, Purnima Pathak & Siew Hwa Ong. (2017) Cost-effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting. Journal of Medical Economics 20:8, pages 832-839.
Read now
Read now
Yusun Hu & Lourdes Cantarero-Arévalo. (2016) Ethnic differences in adverse drug reactions to asthma medications: a systematic review. Journal of Asthma 53:1, pages 69-75.
Read now
Read now
Eylem Sercan Özgür, Cengiz Özge, Ahmet Ïlvan & Sibel Atış Naycı. (2013) Assessment of Long-term Omalizumab Treatment in Patients with Severe Allergic Asthma Long-term Omalizumab Treatment in Severe Asthma. Journal of Asthma 50:6, pages 687-694.
Read now
Read now
Articles from other publishers (22)
Tyler Pitre, Tanvir Jassal, Albi Angjeli, Vineeth Jarabana, Sricherry Nannapaneni, Ayesha Umair, Muizz Hussain, Gareth Leung, Sarah Kirsh, Johnny Su, Kairavi Desai, Jade Coyne, Sindu Mohan & Dena Zeraatkar. (2023) A comparison of the effectiveness of biologic therapies for asthma. Annals of Allergy, Asthma & Immunology 130:5, pages 595-606.
Crossref
Crossref
Yuan Wu, Mengfen Huang, Jinyao Zhong, Yue Lu, Kao Gan, Rongyuan Yang, Yuntao Liu, Jiqiang Li & Jiankun Chen. (2023) The clinical efficacy of type 2 monoclonal antibodies in eosinophil-associated chronic airway diseases: a meta-analysis. Frontiers in Immunology 14.
Crossref
Crossref
Lorenzo Salvati, Francesco Liotta, Francesco Annunziato & Lorenzo Cosmi. (2022) Therapeutical Targets in Allergic Inflammation. Biomedicines 10:11, pages 2874.
Crossref
Crossref
Serafeim Chrysovalantis Kotoulas, Ioanna Tsiouprou, Eva Fouka, Athanasia Pataka, Despoina Papakosta & Konstantinos Porpodis. (2022) Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma. Journal of Personalized Medicine 12:2, pages 165.
Crossref
Crossref
Regina Maria de Carvalho-Pinto1, José Eduardo Delfini Cançado2, Marcia Margaret Menezes Pizzichini3, Jussara Fiterman4, Adalberto Sperb Rubin5,6, Alcindo Cerci Neto7,8, Álvaro Augusto Cruz9,10Ana Luisa Godoy Fernandes11, Ana Maria Silva Araujo12, Daniela Cavalet Blanco13, Gediel Cordeiro Junior14,15, Lilian Serrasqueiro Ballini Caetano11, Marcelo Fouad Rabahi16, Marcelo Bezerra de Menezes17, Maria Alenita de Oliveira18, Marina Andrade Lima19 & Paulo Márcio Pitrez20. (2021) 2021 Brazilian Thoracic Association recommendations for the management of severe asthma. Jornal Brasileiro de Pneumologia, pages e20210273.
Crossref
Crossref
Lêda Maria Rabelo, Rebecca Saray Marchesini Stival, Diogo Drevenowski, Joel Serafini, Giovanna Lemes Leão, Matheus Fernando Rietter Quintino Ferreira & Fabio Marcelo Costa. (2021) Clinical evolution of a severe asthmatics group in the use of immunobiological therapy in a Brazilian Public Hospital. Revista da Associação Médica Brasileira 67:7, pages 931-936.
Crossref
Crossref
Katrine Prætorius, Daniel P. Henriksen, Johannes M. Schmid, Pernille Printzlau, Lars Pedersen, Hanne Madsen, Ehm A. Andersson, Louise Klokker Madsen & Bo L. Chawes. (2021)
Indirect comparison of efficacy of dupilumab
versus
mepolizumab and omalizumab for severe type 2 asthma
. ERJ Open Research 7:3, pages 00306-2021.
Crossref
Crossref
Jean Bousquet, Marc Humbert, Peter G. Gibson, Konstantinos Kostikas, Xavier Jaumont, Pascal Pfister & Francis Nissen. (2021) Real-World Effectiveness of Omalizumab in Severe Allergic Asthma: A Meta-Analysis of Observational Studies. The Journal of Allergy and Clinical Immunology: In Practice 9:7, pages 2702-2714.
Crossref
Crossref
Daniel P. Henriksen, Uffe Bodtger, Kirsten Sidenius, Niels Maltbaek, Lars Pedersen, Hanne Madsen, Ehm A. Andersson, Ole Norgaard, Louise K. Madsen & Bo L. Chawes. (2020) Efficacy of omalizumab in children, adolescents, and adults with severe allergic asthma: a systematic review, meta-analysis, and call for new trials using current guidelines for assessment of severe asthma. Allergy, Asthma & Clinical Immunology 16:1.
Crossref
Crossref
A.N. Frix, F. Schleich, V. Paulus, F. Guissard, M. Henket & R. Louis. (2020) Effectiveness of omalizumab on patient reported outcomes, lung function, and inflammatory markers in severe allergic asthma. Biochemical Pharmacology 179, pages 113944.
Crossref
Crossref
Ioana Agache, Claudio Rocha, Jessica Beltran, Yang Song, Margarita Posso, Ivan Solà, Pablo Alonso‐Coello, Cezmi Akdis, Mubeccel Akdis, Giorgio W. Canonica, Thomas Casale, Tomas Chivato, Jonathan Corren, Stefano Del Giacco, Thomas Eiwegger, Davide Firinu, James E. Gern, Eckard Hamelmann, Nicola Hanania, Mika Mäkelä, Irene Hernández Martín, Parameswaran Nair, Liam O'Mahony, Nikolaos G. Papadopoulos, Alberto Papi, Hae‐Sim Park, Luis Pérez de Llano, Santiago Quirce, Joaquin Sastre, Mohamed Shamji, Jurgen Schwarze, Carlos Canelo‐Aybar, Oscar Palomares & Marek Jutel. (2020) Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma. Allergy 75:5, pages 1043-1057.
Crossref
Crossref
Marcia Margaret Menezes Pizzichini, Regina Maria de Carvalho-Pinto, José Eduardo Delfini Cançado, Adalberto Sperb Rubin,, Alcindo Cerci Neto, Alexandre Pinto Cardoso, Alvaro Augusto Cruz, Ana Luisa Godoy Fernandes, Daniella Cavalet Blanco, Elcio Oliveira Vianna, Gediel Cordeiro Junior, José Angelo Rizzo, Leandro Genehr Fritscher, Lilian Serrasqueiro Ballini Caetano, Luiz Fernando Ferreira Pereira, Marcelo Fouad Rabahi, Maria Alenita de Oliveira, Marina Andrade Lima, Marina Buarque de Almeida, Rafael Stelmach, Paulo Márcio Pitrez & Alberto Cukier. (2020) 2020 Brazilian Thoracic Association recommendations for the management of asthma. Jornal Brasileiro de Pneumologia 46:1.
Crossref
Crossref
Gilda Varricchi, Giancarlo Marone, Giuseppe Spadaro, Michele Russo, Francescopaolo Granata, Arturo Genovese & Gianni Marone. (2019) Novel Biological Therapies in Severe Asthma: Targeting the Right Trait. Current Medicinal Chemistry 26:16, pages 2801-2822.
Crossref
Crossref
Matshediso C. Mokoka, Melissa J. McDonnell, Elaine MacHale, Breda Cushen, Fiona Boland, Sarah Cormican, Christina Doherty, Frank Doyle, Richard W. Costello & Garrett Greene. (2019) Inadequate assessment of adherence to maintenance medication leads to loss of power and increased costs in trials of severe asthma therapy: results from a systematic literature review and modelling study. European Respiratory Journal 53:5, pages 1802161.
Crossref
Crossref
Molly M. Jeffery, Nilay D. Shah, Pinar Karaca-Mandic, Joseph S. Ross & Matthew A. Rank. (2018) Trends in Omalizumab Utilization for Asthma: Evidence of Suboptimal Patient Selection. The Journal of Allergy and Clinical Immunology: In Practice 6:5, pages 1568-1577.e4.
Crossref
Crossref
Regina Maria de Carvalho-Pinto, Rosana Câmara Agondi, Pedro Giavina-Bianchi, Alberto Cukier & Rafael Stelmach. (2017) Omalizumab in patients with severe uncontrolled asthma: well-defined eligibility criteria to promote asthma control. Jornal Brasileiro de Pneumologia 43:6, pages 487-489.
Crossref
Crossref
Abdulaziz Alhossan, Christopher S. Lee, Karen MacDonald & Ivo Abraham. (2017) “Real-life” Effectiveness Studies of Omalizumab in Adult Patients with Severe Allergic Asthma: Meta-analysis. The Journal of Allergy and Clinical Immunology: In Practice 5:5, pages 1362-1370.e2.
Crossref
Crossref
I. Abraham, A. Alhossan, C. S. Lee, H. Kutbi & K. MacDonald. (2016) ‘Real-life’ effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review. Allergy 71:5, pages 593-610.
Crossref
Crossref
Marco Caminati, Gianenrico Senna, Massimo Guerriero, Anna Rita Dama, Fulvia Chieco-Bianchi, Giorgia Stefanizzi, Marcello Montagni & Erminia Ridolo. (2015) Omalizumab for severe allergic asthma in clinical trials and real-life studies: What we know and what we should address. Pulmonary Pharmacology & Therapeutics 31, pages 28-35.
Crossref
Crossref
Tianwen Lai, Shaobin Wang, Zhiwei Xu, Chao Zhang, Yun Zhao, Yue Hu, Chao Cao, Songmin Ying, Zhihua Chen, Wen Li, Bin Wu & Huahao Shen. (2015) Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis. Scientific Reports 5:1.
Crossref
Crossref
Rebecca Normansell, Samantha Walker, Stephen J Milan, E. Haydn Walters & Parameswaran Nair. (2014) Omalizumab for asthma in adults and children. Cochrane Database of Systematic Reviews.
Crossref
Crossref
G.-J. Braunstahl, C.-W. Chen, R. Maykut, P. Georgiou, G. Peachey & J. Bruce. (2013) The eXpeRience registry: The ‘real-world’ effectiveness of omalizumab in allergic asthma. Respiratory Medicine 107:8, pages 1141-1151.
Crossref
Crossref